Brad Whitford
Chief Accounting Officer
Replay available
cbdMD, Inc. (AMEX: YCBD) Q3 2025 earnings conference call, held 2025-08-14. Replay captured from the company's public earnings webcast.

Chief Accounting Officer
Chief Executive Officer and Chief Financial Officer
Analyst, Maxim Group
Analyst, Lismore Partners LLC
Good afternoon. Welcome to CBDMD's third quarter fiscal 2025 results conference call. This afternoon, the company issued a press release that provided an overview of its third quarter results, which followed the filings of its quarterly report on Form 10-Q. Today's conference call is being recorded and will be available online along with our earning press release covering our financial results and non-GAAP presentation. at cbdmds.com in accordance with CBDMD's retention policies. All participants on this call will be in a listen-only mode. The call will be followed by a question-and-answer session. At this time, I would now like to turn the conference over to Brad Whitford, the company's chief accounting officer. Brad, please go ahead. Thank you, Ranju, and thank you all for joining CBDMD's June 30, 2025, third quarter fiscal 2025 earnings call and update. On the call today, we also have Ronan Kennedy, our CEO and Chief Financial Officer. We'd like to remind everyone that various remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CBDMD cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicated, including risks described in the company's annual report on Form 10-K, for the year ended September 30th, 2024, and our other filings with the SEC, all of which can be reviewed on the company's website at www.cbdmd.com or on the SEC's website at www.sec.gov. Any forward-looking statements made on this conference call speak only as of today's date, Thursday, August 14th, 2025, and CBDMD does not intend to update any of these forward-look...